1. 14C-Sulphamethazine (4-amino-N-(4,6-dimethyl-2-pyrimidinyl)benzene-[U-14C]-sulphonamide; 220 mg/kg of body weight) was given orally or i.v. to lactating dairy cows. Milk collected from 0-48 h after dosing accounted for 2.0% (oral dose) and 1.1% (i.v. dose) of the total 14C-activity administered. 2. Sulphamethazine accounted for 70-79% (oral dose) and 54-75% (i.v. dose) of the total 14C in milk samples collected from 0-48 h after dosing. N4-acetylsulphamethazine accounted for 1-2% (oral dose) and 1-4% (i.v. dose) of the 14C in milk. 3. The major 14C-labelled metabolite in the milk was isolated and identified as the N4-lactose conjugate of sulphamethazine, a unique type of metabolite not previously reported. This metabolite accounted for 10-14% (oral dose) and 9-20% (i.v. dose) of the 14C-activity in the milk collected from 0-48 h after dosing with 14C-sulphamethazine. 4. N4-lactose conjugates of sulphapyridine, sulphamerazine, sulphathiazole, sulphadimethoxine and sulphaquinoxaline were present in the milk from cows orally dosed with these five sulphonamide drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00498259209049899 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An analytical cross-sectional study on optimal (timely or cumulative age-appropriate) routine childhood immunization coverage in the communities of Ebonyi state, Nigeria.
Sci Rep
January 2025
Department of Anaesthesia, Alex Ekwueme Federal University Teaching Hospital Abakaliki (AEFUTHA), Abakaliki, Ebonyi State, Nigeria.
Optimal (timely or cumulative age-appropriate) routine childhood immunization coverage (the receipt of every recommended vaccine dose at the recommended age and time-interval between doses) will enhance optimal protection against vaccine-preventable infectious diseases (VPDs) which have been causing significant morbidity and mortality and recurring outbreaks among children younger than five years. This study evaluated optimal routine childhood immunization coverage, and the predictors, in Ebonyi state, Nigeria. This study was a baseline cross-sectional household survey within a cluster-randomised controlled trial and was conducted from July 2 to 16, 2022 among consenting mother-child pairs, in which the children were aged 5-23 months (subdivided into 5-11 and 12-23 months), in 16 randomly selected geographical clusters where the primary health care (PHC) facilities were providing maternal and child health care services including weekly routine childhood immunization.
View Article and Find Full Text PDFSclerotherapy with low-dose 5% ethanolamine oleate in oral vascular anomalies: a retrospective study.
Oral Surg Oral Med Oral Pathol Oral Radiol
January 2025
Diagnostic Center for Oral Diseases, School of Dentistry, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil. Electronic address:
Objective: To describe the characteristics and outcomes of a cohort of patients with oral vascular anomalies (OVA) treated with sclerotherapy using 5% ethanolamine oleate at a dosage of 0.1 mL per 10 mm of lesion size.
Study Design: Sixty-seven patients were selected from a review of 300 medical records of individuals who had been diagnosed with OVA.
Characterization of human alcohol dehydrogenase 4 and aldehyde dehydrogenase 2 as enzymes involved in the formation of 5-carboxylpirfenidone, a major metabolite of pirfenidone.
Drug Metab Dispos
January 2025
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.
Pirfenidone (PIR) is used in the treatment of idiopathic pulmonary fibrosis. After oral administration, it is metabolized by cytochrome P450 1A2 to 5-hydroxylpirfenidone (5-OH PIR) and further oxidized to 5-carboxylpirfenidone (5-COOH PIR), a major metabolite excreted in the urine (90% of the dose). This study aimed to identify enzymes that catalyze the formation of 5-COOH PIR from 5-OH PIR in the human liver.
View Article and Find Full Text PDFDNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
J Nucl Med
January 2025
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;
Novel radiation sensitizers, including inhibitors targeting DNA damage response, have been developed to enhance the efficacy of anticancer treatments that induce DNA damage in cancer cells. Peposertib, a potent, selective, and orally administered inhibitor of DNA-dependent protein kinase, impedes the nonhomologous end-joining mechanism for DNA double-strand break (DSB) repair. We investigated radioimmunotherapy alone or with peposertib in preclinical models of renal cell carcinoma (RCC) or prostate cancer.
View Article and Find Full Text PDFNormal tissue complication probability model predicting taste impairment in head and neck cancer patients: Evaluating the taste bud bearing tongue mucosa as a predictor.
Radiother Oncol
January 2025
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address:
Background/purpose: Taste impairment is a common yet complex toxicity of head and neck cancer (HNC) radiotherapy treatment that may affect quality of life of survivors. This study aimed to predict acute and late taste impairment using taste bud bearing tongue mucosa as a new taste-specific organ-at-risk compared to full oral cavity as identified in previous studies.
Materials/methods: Included HNC patients were treated with curative radiotherapy between 2007 and 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!